Multicenter retrospective observational study for hepatitis B virus reactivation-related liver complications in HBsAg-positive patients with diffuse large B-cell lymphoma following rituximab-containing chemotherapy - Retrospective study for hepatitis B virus reactivation in HBsAg-positive lymphoma patients

Department of Hematology, National Cancer Center Hospital0 个研究点目标入组 500 人开始时间: 2017年1月9日最近更新: 2023年10月17日

试验速览

暂无简介。

•Exclusion criteria for HBsAg-positive group: 1) Seropositive for hepatitis C virus 2) Seropositive for human immunodeficiency virus 3) Alanine transaminase level of 100 U/L or more at baseline 4) Lymphoma involvement of central nervous system at diagnosis of DLBCL regardless of primary or secondary one 5) Diagnosed as having intravascular lymphoma or primary testicular lymphoma 6) Have a history of systemic chemotherapy for hematological malignancies or solid tumors 7) Diagnosed as having decompensated cirrhosis or hepatocellular carcinoma at diagnosis of DLBCL or have a history of decompensated cirrhosis or hepatocellular carcinoma Exclusion criteria for HBsAg-negative group: 1) Seropositive for HBsAg before or at diagnosis of DLBCL 2) Seropositive for hepatitis C virus 3) Seropositive for human immunodeficiency virus 4) Alanine transaminase level of 100 U/L or more at baseline 5) Lymphoma involvement of central nervous system at diagnosis of DLBCL regardless of primary or secondary one 6) Diagnosed as having intravascular lymphoma or primary testicular lymphoma 7) Have a history of systemic chemotherapy for hematological malignancies or solid tumors 8) Diagnosed as having decompensated cirrhosis or hepatocellular carcinoma at diagnosis of DLBCL or have a history of decompensated cirrhosis or hepatocellular carcinoma

发起方

Department of Hematology, National Cancer Center Hospital